In an advance for precision oncology, the largest published study to date on molecular residual disease (MRD) detection in stage 3 colon cancer has demonstrated the prognostic capabilities of Guardant ...
“The data suggest that not only the presence of ctDNA, but the amount of ctDNA, as identified by Guardant Reveal may help refine risk beyond standard TNM staging, and could be used to guide adjuvant ...
Data published in Journal of Clinical Oncology supports routine use of circulating tumor DNA (ctDNA) testing in management of stage III colon cancer patients Researchers found that about 20 percent of ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results